Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR0302 plus Prednisone for First-Line Chronic GVHD
NCT04146207Phase 1Completed
- Sponsor
- Shanghai General Hospital
- Start
- Apr 2020
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ivarmacitinib in chronic graft-versus-host disease (cGVHD), sponsored by Shanghai General Hospital. Primary endpoint: Safety and tolerability of SHR0302 and prednisone. Started Apr 2020; status: completed.
02
Drugs
ivarmacitinib
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT04146207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04146207.